Do analysts prefer ATHA or CUE?

Athira Pharma currently has a consensus price target of $4.00, suggesting a potential downside of 51.34%. Given Athira Pharma's higher possible upside, analysts plainly believe Athira Pharma is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, PLYX or ATHA?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A N/A -$0.05 N/A Athira Pharma N/A N/A -$96.94M -$9.68 N/A

Is PLYX or ATHA more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Athira Pharma N/A -107.06% -89.89%

Which has better valuation and earnings, ATHA or ALDX?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$96.94M -$9.68 N/A Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A

Is ATHA or ALDX more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -107.06% -89.89% Aldeyra Therapeutics N/A -57.34% -36.33%

Which has preferable earnings and valuation, ATHA or PEPG?

PepGen is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$96.94M -$9.68 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is ATHA or PEPG more profitable?

PepGen's return on equity of -59.89% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -107.06% -89.89% PepGen N/A -59.89% -49.62%

Do analysts rate ATHA or LIXT?

Athira Pharma presently has a consensus price target of $4.00, suggesting a potential downside of 51.34%. Given Athira Pharma's higher possible upside, research analysts plainly believe Athira Pharma is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ATHA or LIXT?

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$96.94M -$9.68 N/A Lixte Biotechnology N/A N/A -$6.01M -$1.13 N/A

Is ATHA or LIXT more profitable?

Athira Pharma's return on equity of -107.06% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -107.06% -89.89% Lixte Biotechnology N/A -134.91% -95.61%

Athira Pharma (ATHA) Competitors

Compare

ATHA vs. CUE, PLYX, ALDX, PEPG, and LIXT

Should you buy Athira Pharma stock or one of its competitors? MarketBeat compares Athira Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Athira Pharma include Cue Biopharma (CUE), Polaryx Therapeutics (PLYX), Aldeyra Therapeutics (ALDX), PepGen (PEPG), and Lixte Biotechnology (LIXT). These companies are all part of the "pharmaceutical products" industry.

How does Athira Pharma compare to Cue Biopharma?

Athira Pharma (NASDAQ:ATHA) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Athira Pharma has a beta of 2.79, suggesting that its stock price is 179% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market.

Cue Biopharma has higher revenue and earnings than Athira Pharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
Cue Biopharma	$32.73M	3.63	-$26.60M	-$5.58	N/A

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by company insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Athira Pharma's average media sentiment score of 0.00 equaled Cue Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
Cue Biopharma	Neutral

Athira Pharma currently has a consensus price target of $4.00, suggesting a potential downside of 51.34%. Given Athira Pharma's higher possible upside, analysts plainly believe Athira Pharma is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Athira Pharma has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
Cue Biopharma	-59.65%	-98.30%	-53.69%

Summary

Athira Pharma beats Cue Biopharma on 6 of the 11 factors compared between the two stocks.

How does Athira Pharma compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Athira Pharma (NASDAQ:ATHA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A

Polaryx Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 255.87%. Athira Pharma has a consensus price target of $4.00, suggesting a potential downside of 51.34%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Polaryx Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Polaryx Therapeutics' average media sentiment score of 0.00 equaled Athira Pharma'saverage media sentiment score.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Athira Pharma	Neutral

57.1% of Athira Pharma shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Polaryx Therapeutics' return on equity of 0.00% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Athira Pharma	N/A	-107.06%	-89.89%

Summary

Polaryx Therapeutics beats Athira Pharma on 6 of the 9 factors compared between the two stocks.

How does Athira Pharma compare to Aldeyra Therapeutics?

Athira Pharma (NASDAQ:ATHA) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Athira Pharma has a beta of 2.79, indicating that its stock price is 179% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Aldeyra Therapeutics' return on equity of -57.34% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

Athira Pharma currently has a consensus price target of $4.00, indicating a potential downside of 51.34%. Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 142.29%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Athira Pharma's average media sentiment score of 0.00 equaled Aldeyra Therapeutics'average media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
Aldeyra Therapeutics	Neutral

Summary

Aldeyra Therapeutics beats Athira Pharma on 8 of the 11 factors compared between the two stocks.

How does Athira Pharma compare to PepGen?

Athira Pharma (NASDAQ:ATHA) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

PepGen's return on equity of -59.89% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
PepGen	N/A	-59.89%	-49.62%

Athira Pharma presently has a consensus target price of $4.00, suggesting a potential downside of 51.34%. PepGen has a consensus target price of $11.50, suggesting a potential upside of 553.41%. Given PepGen's stronger consensus rating and higher possible upside, analysts clearly believe PepGen is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

PepGen is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 19.8% of Athira Pharma shares are held by company insiders. Comparatively, 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Athira Pharma has a beta of 2.79, suggesting that its stock price is 179% more volatile than the broader market. Comparatively, PepGen has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market.

In the previous week, Athira Pharma's average media sentiment score of 0.00 equaled PepGen'saverage media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
PepGen	Neutral

Summary

PepGen beats Athira Pharma on 8 of the 11 factors compared between the two stocks.

How does Athira Pharma compare to Lixte Biotechnology?

Athira Pharma (NASDAQ:ATHA) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Athira Pharma's return on equity of -107.06% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
Lixte Biotechnology	N/A	-134.91%	-95.61%

Athira Pharma has a beta of 2.79, suggesting that its share price is 179% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 19.8% of Athira Pharma shares are held by company insiders. Comparatively, 9.5% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lixte Biotechnology is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

In the previous week, Lixte Biotechnology had 1 more articles in the media than Athira Pharma. MarketBeat recorded 1 mentions for Lixte Biotechnology and 0 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 equaled Lixte Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
Lixte Biotechnology	Neutral

Athira Pharma presently has a consensus price target of $4.00, suggesting a potential downside of 51.34%. Given Athira Pharma's higher possible upside, research analysts plainly believe Athira Pharma is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Athira Pharma beats Lixte Biotechnology on 7 of the 10 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHA vs. The Competition

Export

Metric	Athira Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$32.42M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.85	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.46
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	N/A	8.66	10.96	6.46
Net Income	-$96.94M	$23.81M	$3.57B	$337.01M
7 Day Performance	N/A	3.39%	2.12%	1.69%
1 Month Performance	-4.53%	10.81%	5.25%	3.81%
1 Year Performance	148.34%	62.61%	33.29%	23.90%

Athira Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHA Athira Pharma	N/A	N/A	$4.00 +∞	+148.3%	$32.42M	N/A	N/A	40
CUE Cue Biopharma	0.1723 of 5 stars	$31.56 +3.7%	N/A	-95.4%	$127.82M	$27.47M	N/A	60	Gap Up High Trading Volume
PLYX Polaryx Therapeutics	2.0034 of 5 stars	$2.66 +5.1%	$10.00 +275.9%	N/A	$125.10M	N/A	N/A	11	Analyst Upgrade
ALDX Aldeyra Therapeutics	3.1743 of 5 stars	$2.13 +3.9%	$5.50 +158.2%	-47.3%	$123.66M	N/A	N/A	10
PEPG PepGen	2.6218 of 5 stars	$1.80 +1.1%	$11.50 +538.9%	+44.3%	$123.12M	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athira Pharma (ATHA) Competitors

ATHA vs. CUE, PLYX, ALDX, PEPG, and LIXT

How does Athira Pharma compare to Cue Biopharma?

Summary

How does Athira Pharma compare to Polaryx Therapeutics?

Summary

How does Athira Pharma compare to Aldeyra Therapeutics?

Summary

How does Athira Pharma compare to PepGen?

Summary

How does Athira Pharma compare to Lixte Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athira Pharma (ATHA) Competitors

ATHA vs. CUE, PLYX, ALDX, PEPG, and LIXT

How does Athira Pharma compare to Cue Biopharma?

Which has more volatility and risk, ATHA or CUE?

Which has higher valuation and earnings, ATHA or CUE?

Do insiders and institutionals hold more shares of ATHA or CUE?

Does the media favor ATHA or CUE?

Do analysts prefer ATHA or CUE?

Is ATHA or CUE more profitable?

Summary

How does Athira Pharma compare to Polaryx Therapeutics?

Which has better earnings & valuation, PLYX or ATHA?

Do analysts recommend PLYX or ATHA?

Does the media prefer PLYX or ATHA?

Do institutionals and insiders hold more shares of PLYX or ATHA?

Is PLYX or ATHA more profitable?

Summary

How does Athira Pharma compare to Aldeyra Therapeutics?

Which has more risk and volatility, ATHA or ALDX?

Which has better valuation and earnings, ATHA or ALDX?

Is ATHA or ALDX more profitable?

Do analysts recommend ATHA or ALDX?

Do insiders & institutionals believe in ATHA or ALDX?

Does the media favor ATHA or ALDX?

Summary

How does Athira Pharma compare to PepGen?

Is ATHA or PEPG more profitable?

Do analysts rate ATHA or PEPG?

Which has preferable earnings and valuation, ATHA or PEPG?

Do insiders & institutionals have more ownership in ATHA or PEPG?

Which has more volatility and risk, ATHA or PEPG?

Does the media favor ATHA or PEPG?

Summary

How does Athira Pharma compare to Lixte Biotechnology?

Is ATHA or LIXT more profitable?

Which has more volatility & risk, ATHA or LIXT?

Do institutionals and insiders have more ownership in ATHA or LIXT?

Which has stronger valuation and earnings, ATHA or LIXT?

Does the media refer more to ATHA or LIXT?

Do analysts rate ATHA or LIXT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools